PFE Stock: Pfizer Inc. — Profile, Analysis & Investor Guide (2026)
Pfizer Inc. is a global biopharmaceutical leader dedicated to discovering, developing, and manufacturing innovative medicines and vaccines. — Updated June 2026 with current price, P/E ratio, analyst ratings, financials, and investor insights.
Pfizer Inc. (PFE) remains a cornerstone of the global healthcare sector, navigating a significant transition as it moves beyond the peak of its COVID-19 product revenues. The company has aggressively pivoted toward oncology and rare diseases, fueled by its multi-billion dollar acquisition of Seagen. While the healthcare landscape is distinct from consumer-focused lists like the Complete List Of Food & Beverage Companies Listed On U.S. Exchanges, Pfizer’s massive scale and distribution network allow it to maintain a dominant presence in pharmacies worldwide. For income-seeking investors, Pfizer’s high dividend yield has made it a frequent topic of discussion alongside other high-yield defensive sectors.
As technology continues to merge with medicine, Pfizer leverages advanced computational biology and AI, mirroring the research-intensive nature of the firms on the Complete List Of Semiconductor Companies Listed On U.S. Exchanges. This technological edge is vital for its robust pipeline of new molecular entities. Interestingly, Pfizer’s broad corporate influence even touches the marketing world, where brand partnerships often overlap with the visibility seen in the List Of Publicly Traded Sports Companies. Despite recent stock price consolidation, Pfizer’s low beta of 0.61 continues to provide a defensive cushion for diversified portfolios during periods of market turbulence.
Key Takeaways — PFE Stock
With a yield of 6.72%, Pfizer is one of the highest-paying dividend stocks in the S&P 500, appealing strongly to income investors.
The forward P/E ratio of 9.00 suggests the stock may be undervalued if the company successfully executes its new product launches.
A beta of 0.61 indicates that Pfizer is significantly less volatile than the broader market, serving as a classic defensive play.
The integration of Seagen is the core of Pfizer’s long-term growth strategy to offset patent expirations on older blockbuster drugs.
PFE Stock Health Score
Scores out of 10 based on current fundamentals, valuation, momentum and income data.
PFE — Live Stock Chart
Real-time price chart powered by TradingView.
PFE — Key Statistics & Valuation
Core financial data as of June 2026.
| Valuation | Value | Financials | Value |
|---|---|---|---|
| Market Cap | $145.91B | Revenue (TTM) | $59.50B |
| P/E Ratio (TTM) | 19.56 | Net Income | $7.42 billion |
| Forward P/E | 9.00 | EPS (TTM) | $1.31 |
| Price/Sales | 2.45 | Gross Margin | 59.20% |
| Price/Book | 1.62 | Net Margin | 12.47% |
| PEG Ratio | 1.25 | ROE | 19.47% |
| Beta | 0.61 | Debt/Equity | 0.74 |
| 52-Week High | $28.75 | 52-Week Low | $23.11 |
| Avg Daily Volume | 37.00 million | YTD Return | 1.87% |
| 1-Year Return | 0.14% | 5-Year Return | 32.60% |
| Dividend Yield | 6.72% | Payout Ratio | 131.3% |
| Analyst Rating | Hold | Price Target | $28.00 |
| Sector | Healthcare | Industry | Pharmaceuticals |
| CEO | Albert Bourla | Employees | 88,000 |
| Founded | 1849 | Headquarters | New York, New York |
PFE — Business Overview
Broad portfolio of vaccines and medicines across oncology, immunology, cardiology, and rare diseases, including blockbusters like Eliquis and Vyndaqel.
Revenue is derived from the global sale of prescription pharmaceuticals and vaccines to wholesalers, retailers, hospitals, and government agencies.
Unmatched R&D budget, deep regulatory expertise, and one of the world’s most sophisticated supply chains for biologics and mRNA products.
The integration of Seagen’s ADC technology (Antibody-Drug Conjugates) which aims to double Pfizer’s oncology revenue by 2030.
PFE — Financial Performance Snapshot
| 📈 Growth | Value | 📊 Profitability | Value | 🎯 Valuation | Value |
|---|---|---|---|---|---|
| Revenue Growth YoY | -12.4% | Gross Margin | 59.20% | P/E Ratio | 19.56 |
| EPS Growth YoY | -18.2% | Net Margin | 12.47% | Forward P/E | 9.00% |
| 5Y Revenue CAGR | 8.5% | ROE | 19.47% | PEG Ratio | 1.25 |
| Free Cash Flow | $6.8B | Operating Margin | 15.2% | Price/Sales | 2.45 |
PFE — Analyst Ratings & Price Target
Based on 22 analysts covering PFE as of June 2026.
High: $34.00 | Low: $24.00 | Upside from current: 9.16%
6 Buy | 14 Hold | 2 Sell ratings from covering analysts.
JP Morgan maintained its Neutral rating citing the need for clearer pipeline execution in the oncology segment.
PFE Technical Analysis
Real-time buy/sell signals from TradingView.
PFE — Pros & Cons
✓ Massive Dividend Income
The 6.72% yield is highly attractive for retirees and conservative investors looking for steady quarterly cash flow.
✗ Patent Cliffs
Pfizer faces significant patent expirations on major drugs like Eliquis over the next few years, creating a revenue gap.
✓ Attractive Valuation
A forward P/E of 9.00 indicates the stock is trading well below its long-term average and its major pharmaceutical peers.
✗ Post-COVID Revenue Slump
Replacing the tens of billions in revenue from Comirnaty and Paxlovid remains a major hurdle for the company.
✓ Strong Oncology Pipeline
The Seagen acquisition has loaded Pfizer with high-potential ADC therapies that could drive growth for a decade.
✗ R&D Failures
Drug development is inherently risky; any major failure in late-stage clinical trials can cause sharp stock price drops.
Who Should Consider PFE?
Income-oriented investors and contrarian value seekers who believe the market has overly penalized Pfizer’s COVID transition.
Aggressive growth investors or momentum traders looking for immediate triple-digit gains in the technology sector.
3 to 5 years, allowing time for the new oncology pipeline to mature and the patent cliff impact to be absorbed.
Standard taxable accounts for the high dividend or IRAs to shield the substantial quarterly payouts from taxes.
PFE vs Competitors
| Company | Ticker | Market Cap | P/E | Rev Growth | Net Margin | Dividend | 1Y Return |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. ★ | PFE | $145.91B | 19.56 | -12.4% | 12.47% | 6.72% | 0.14% |
| Johnson & Johnson | JNJ | $380.5B | 12.40 | 3.5% | 21.20% | 3.10% | 5.20% |
| Merck & Co. | MRK | $315.2B | 30.10 | 8.2% | 4.50% | 2.45% | 18.40% |
| AbbVie | ABBV | $302.8B | 22.50 | 2.1% | 10.20% | 3.60% | 24.80% |
PFE — Key Risks
Drug Development Failure
Clinical trial setbacks or FDA rejections of new oncology treatments would severely damage the long-term investment thesis.
Pricing Regulation
Government mandates to lower prescription drug prices in the US could compress profit margins for blockbuster medications like Eliquis.
Dividend Coverage
While currently safe, a prolonged earnings slump could eventually pressure the company’s ability to maintain its high payout ratio.
Interest Rate Exposure
Pfizer carries significant debt from its acquisition strategy; sustained high interest rates could increase debt servicing costs.